PureTech Health Plc Overview
Valuation check: PRTC's ROE is -17.94%, below the Finance sector average of 17.11%.
Get informed when a big investor buys or sells
+ Follow-17.94%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
PureTech Health Plc (PRTC) currently reports a ROE of -17.94%. That is below the Finance sector average of 17.11%. Use the charts on this page to explore PureTech Health Plc's ROE history and peer comparisons.
PureTech Health Plc's ROE of -17.94% is lower than the Finance sector average of 17.11%. That is roughly 204.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but PureTech Health Plc's current -17.94% should be judged against Finance norms (sector average: 17.11%) and against PRTC's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -17.94%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Finance average is 17.11%. From there, open related valuation or income-statement pages for PureTech Health Plc, and consider following PRTC for alerts when major investors trade the stock.
PureTech Health Plc is classified in the Finance sector. On ROE, it currently shows -17.94% versus a sector average near 17.11%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Finance are usually more informative than comparing PRTC with unrelated industries.
